Human parainfluenza virus type 3 (PIV3) can cause severe morbidity and mortality among haematopoietic stem cell transplant (HSCT) recipients. 1, 2 In fact, studies have reported mortality rates of up to 40-50% in adult HSCT patients with PIV3-related pneumonia. 3 Previous reports, however, have focussed almost entirely on the pulmonary manifestations of PIV3 infection in the HSCT population. 4 Extra-pulmonary manifestations of PIV3 infection are rare, but can include meningitis, myopericarditis and parotitis. 5 We report here a nosocomial outbreak of PIV3 involving HSCT recipients, and describe associated haematologic manifestations, including loss of engraftment in severely affected patients.
The clinical manifestations and outcomes of PIV3 infection in 10 hematopoietic SCT (HSCT) recipients were reviewed. Cases were identified during a nosocomial outbreak at the Ottawa Hospital between July and September 2008. Diagnosis of PIV3 infection was confirmed by DFA testing on nasopharyngeal swabs. All infected patients who received a HSCT in the preceding 100 days are included in this report. The median age of patients was 58 (range 14-65). Five were allogeneic transplant recipients (four HLA-matched related donors and one HLA-mismatched unrelated donor), and five received autologous transplants. PIV3 infection was diagnosed at a median of 16 days (range 8-35) post-transplant. The number of affected patients with lower respiratory tract symptoms was 7/10; the remainder had upper respiratory tract symptoms only. Four patients developed respiratory failure, and required admission to the intensive care unit for mechanical ventilation. Of these four, the three most severely affected patients manifested loss of hematopoietic engraftment with hypoplasia or aplasia demonstrated on BM examination. To conclude, in this series, patients with mild to moderate respiratory symptoms secondary to PIV3 infection did not manifest significant cytopenias. However, three of the most severely affected patients experienced profound cytopenias, with loss of engraftment in two of the three. The timing of PIV3 infection in relation to hematopoietic engraftment may be a contributing factor. To our knowledge, severe hematological manifestations of PIV3 infection have not been reported previously. Similar findings have been described in association with respiratory syncytial virus infection in HSCT recipients. In one series, two patients autografted for multiple myeloma showed delayed neutrophil and platelet engraftment after respiratory syncytial virus infection. A third patient, who received an HLA-matched allograft for relapsed multiple myeloma, experienced secondary graft failure shortly after respiratory syncytial virus infection. 6 In addition, there are two case reports in the literature of secondary graft failure following PIV1 infection in pediatric HSCT recipients. 7 Hence, this case series highlights the importance of infection control practices on hospital wards with HSCT recipients, and identifies a potentially under-recognized but important complication of HSCT.
